NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix Reports New Data for Potential First-In-Class Radioenhancer NBTXR3 in Combination with Anti-Pd-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-Pd-1 Exposure
    Nanobiotix Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
    Nanobiotix Announces The Appointment Of Dr. Gary Phillips As Chairman Of The Nanobiotix Supervisory Board



    June 14, 2021

    Bio International Convention

    More info
    June 11, 2021

    Virtual KOL Discussion of Updated Study 1100 Data at ASCO 2021

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation